BRCA1 and hepatocellular carcinoma: BRCA1 and BRCA2 mutation testing is not a part of the treatment paradigm for HCC, but the increased use of molecular profiling for solid tumors may mitigate the difficulty in identifying candidate patients for PARP inhibition therapy.